Use of Mpeg-Plga Nanoparticles to Improve Bioactivity and Hemocompatibility of Streptokinase: In-Vitro and In-Vivo Studies

Use of Mpeg-Plga Nanoparticles to Improve Bioactivity and Hemocompatibility of Streptokinase: In-Vitro and In-Vivo Studies Publisher Pubmed

Hasanpour A¹ ; Esmaeili F¹ ; Hosseini H² ; Amani A^{3, 4}

Show Affiliations

1. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Bioprocess Engineering Group, Industrial and Enviromental Biotechnology Department, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
3. Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran
4. Medical Biomaterials Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran

Source: Materials Science and Engineering C Published:2021

Abstract

Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickly reacts to the drug. Despite these limitations, streptokinase is still the first choice for diseases associated with thrombosis. In this work, streptokinase was encapsulated in mPEG-PLGA nanoparticles to improve its pharmacokinetic properties. The nanoparticles containing the enzyme were prepared by coaxial electrospray and their physicochemical properties, blood compatibility, circulation time and cell toxicity were evaluated. The results showed that the use of mPEG-PLGA nanoparticles to encapsulate the enzyme resulted in prolonged circulation time (up to 120 min) with a slight decrease in its activity. In vivo studies also showed that the nanoparticles containing streptokinase did not have adverse effect on blood biochemistry parameters as well as liver and kidney tissues. As a result, the mPEG-PLGA nanoparticles showed the potential for increasing the biological activity of streptokinase with no important adverse effect. © 2020 Elsevier B.V.

Related Docs

View other Related Docs

1. Preparation of Peg-Grafted Chitosan/Streptokinase Nanoparticles to Improve Biological Half-Life and Reduce Immunogenicity of the Enzyme, International Journal of Biological Macromolecules (2020)

2. Preparation, Optimization and Activity Evaluation of Plga/Streptokinase Nanoparticles Using Electrospray, Advanced Pharmaceutical Bulletin (2017)

3. Protein Corona Variation in Nanoparticles Revisited: A Dynamic Grouping Strategy, Colloids and Surfaces B: Biointerfaces (2019)

4. Introducing Electrospray As a Potent Technique to Deliver Chitosan/Pdna Nanoparticles to Eukaryotic Cells, Journal of Nano Research (2021)

5. N-Acetylcysteine-Plga Nano-Conjugate: Effects on Cellular Toxicity and Uptake of Gadopentate Dimeglumine, IET Nanobiotechnology (2020)

6. Pretreatment With Ultrasonication Reduces the Size of Azelaic Acid-Chitosan Nanoparticles Prepared by Electrospray, Archives of Razi Institute (2018)

7. Evaluation of Drug-Eluting Nanoparticle Coating on Magnesium Alloy for Development of Next Generation Bioabsorbable Cardiovascular Stents, Medical Engineering and Physics (2022)

8. Chitosan Nanoparticles Improve the Effectivity of Miltefosine Against Acanthamoeba, PLoS Neglected Tropical Diseases (2024)

Experts (# of related papers)

View all Related Experts

Seyed Mojtaba Daghighi (1)

Mahdi Mohebali (1)

Style	Citing Format
MLA	Hasanpour A, et al.. "Use of Mpeg-Plga Nanoparticles to Improve Bioactivity and Hemocompatibility of Streptokinase: In-Vitro and In-Vivo Studies." Materials Science and Engineering C, vol. 118, no. , 2021, pp. -.
APA	Hasanpour A, Esmaeili F, Hosseini H, Amani A (2021). Use of Mpeg-Plga Nanoparticles to Improve Bioactivity and Hemocompatibility of Streptokinase: In-Vitro and In-Vivo Studies. Materials Science and Engineering C, 118(), -.
Chicago	Hasanpour A, Esmaeili F, Hosseini H, Amani A. "Use of Mpeg-Plga Nanoparticles to Improve Bioactivity and Hemocompatibility of Streptokinase: In-Vitro and In-Vivo Studies." Materials Science and Engineering C 118, no. (2021): -.
Harvard	Hasanpour A et al. (2021) 'Use of Mpeg-Plga Nanoparticles to Improve Bioactivity and Hemocompatibility of Streptokinase: In-Vitro and In-Vivo Studies', Materials Science and Engineering C, 118(), pp. -.
Vancouver	Hasanpour A, Esmaeili F, Hosseini H, Amani A. Use of Mpeg-Plga Nanoparticles to Improve Bioactivity and Hemocompatibility of Streptokinase: In-Vitro and In-Vivo Studies. Materials Science and Engineering C. 2021;118():-.
BibTex	@article{ author = {Hasanpour A and Esmaeili F and Hosseini H and Amani A}, title = {Use of Mpeg-Plga Nanoparticles to Improve Bioactivity and Hemocompatibility of Streptokinase: In-Vitro and In-Vivo Studies}, journal = {Materials Science and Engineering C}, volume = {118}, number = {}, pages = {-}, year = {2021} }
RIS	TY - JOUR AU - Hasanpour A AU - Esmaeili F AU - Hosseini H AU - Amani A TI - Use of Mpeg-Plga Nanoparticles to Improve Bioactivity and Hemocompatibility of Streptokinase: In-Vitro and In-Vivo Studies JO - Materials Science and Engineering C VL - 118 IS - SP - EP - PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract